Abbreviations: ACS 5 acute coronary syndrome; AF 5 atrial fi brillation; AIS 5 arterial ischemic stroke; APLA 5 antiphospolipid antibodies; ASA 5 acetylsalicylic acid; AT9 5 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines; BMS 5 bare-metal stent; CABG 5 coronary artery bypass graft; CAD 5 coronary artery disease; CDT 5 catheterdirected thrombosis; CHADS 2 5 congestive heart failure, hypertension, age Ն 75 years, diabetes mellitus, prior stroke or transient ischemic attack; CSVT 5 cerebral sinovenous thrombosis; CTPH 5 chronic thromboembolic pulmonary hypertension; CUS 5 compression ultrasound; CVAD 5 central venous access device; DES 5 drug-eluting stent; GCS 5 graduated compression stockings; HFS 5 hip fracture surgery; HIT 5 heparin-induced thrombocytopenia; HITT 5 heparin-induced thrombocytopenia complicated by thrombosis; IA 5 intraarterial; ICH 5 intracerebral hemorrhage; IE 5 infective endocarditis; INR 5 international normalized ratio; IPC 5 intermittent pneumatic compression; IPCD 5 intermittent pneumatic compression device; IVC 5 inferior vena cava; LDUH 5 low-dose unfractionated heparin; LMWH 5 low-molecularweight heparin; LV 5 left ventricular; MBTS 5 modifi ed BlalockTaussig shunt; MR 5 magnetic resonance; PAD 5 peripheral artery disease; PCI 5 percutaneous coronary inter vention; PE 5 pulmonary embolism; PFO 5 patent foramen ovale; PMBV 5 percutaneous mitral balloon valvotomy; PTS 5 postthrombotic syndrome; PVT 5 prosthetic valve thrombosis; r-tPA 5 recombinant tissue plasminogen activator; RVT 5 renal vein thrombosis; SC 5 subcutaneous; TEE 5 transesophageal echocardiography; THA 5 total hip arthroplasty; TIA 5 transient ischemic attack; TKA 5 total knee arthroplasty; UAC 5 umbilical arterial catheter; UEDVT 5 upperextremity DVT; UFH 5 unfractionated heparin; US 5 ultrasound; UVC 5 umbilical venous catheter; VAD 5 ventricular assist device; VKA 5 vitamin K antagonist
T he eighth iteration of the American College of Chest Physicians Antithrombotic Guidelines presented, in a paper version, a narrative evidence summary and rationale for the recommendations, a small number of evidence profi les summarizing bodies of evidence, and some articles with quite extensive summary tables of primary studies. In total, this represented 600 recommendations summarized in 968 pages of text. Many readers responded that the result was too voluminous for their liking or practical use.
Cognizant of this feedback, we worked hard to minimize the length of the text for the ninth iteration of the guidelines Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (AT9) without sacrifi cing key content. A number of topic editors found our shortening edits draconian, but we were determined to produce the leanest product possible.
There were, however, a number of obstacles. In what we believe is a key advance in AT9, we conducted a systematic review of what is known about patients' values and preferences regarding antithrombotic therapy and included the results as an article in AT9. In another forward step, we recognized the problems with asymptomatic thrombosis as a surrogate outcome, and devised strategies to estimate reductions in symptomatic DVT and pulmonary embolism with antithrombotic prophylaxis. We felt it important to explain this innovation to users of AT9, and this meant another article.
We included, for the fi rst time, an article on diagnosis addressing patients with symptoms and signs suggesting DVT. We increased the range of interventions we have covered, resulting in additional recommendations. Finally, we produced many summary of fi ndings tables, which offer extremely succinct and informative presentations of best estimates of effect and the confi dence associated with those estimates.
If published in the same fashion as the Antithrombotic and Thrombolytic Therapy, 8th ed: American tables) and some tables summarizing the methods and results, and the risk of bias, associated with the individual studies that contributed to the evidence profi les and summary of fi ndings tables.
The world of medical information is rapidly becoming a world of electronic storage and presentation of primary studies, recommendations, and a wide variety of other information of interest to health care prac titioners. Although our abbreviated paper copy presentation represents a necessary response to a challenging situation, it is also a harbinger of the increasingly electronic world of medical information into which future editions of guidelines are destined to move.
Summary of Recommendations
Note on Shaded Text: Throughout this guideline, shading is used within the summary of recommendations sections to indicate recommendations that are newly added or have been changed since the publication of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines (8th Edition). Recommendations that remain unchanged are not shaded.
Evidence-Based Management of Anticoagulant Therapy
For further details, see Holbrook et al. 1 
Loading Dose for Initiation of Vitamin K Antagonist (VKA) Therapy

2.1.
For patients suffi ciently healthy to be treated as outpatients, we suggest initiating VKA therapy with warfarin 10 mg daily for the fi rst 2 days followed by dosing based on international normalized ratio (INR) measurements rather than starting with the estimated maintenance dose (Grade 2C) .
Initial Dose Selection and Pharmacogenetic Testing
For patients initiating VKA therapy, we
recommend against the routine use of pharmacogenetic testing for guiding doses of VKA (Grade 1B) .
Initiation Overlap for Heparin and VKA
2.3.
For patients with acute VTE, we suggest that VKA therapy be started on day 1 or 2 of low-molecular-weight heparin (LMWH) or low-dose unfractionated heparin (UFH) therapy rather than waiting for several days to start (Grade 2C) .
College of Chest Physicians Antithrombotic Guidelines, this would have resulted in a document with . 850 pages of paper text, an unacceptable length. Given this and with the advice of the journal, we decided to adopt a highly focused print version that includes only this executive summary and the following articles:
• An introduction describing the major innovations in AT9 • A methods article explaining how we developed the guidelines (a potential model for other guideline groups interested in optimal rigor) • Recommendations and grading from each article embedded in the table of contents of each article
Those seeking the rationale for the recommendations, including the supporting evidence, should access the online version of the guideline ( http:// http://chestjournal.chestpubs.org/content/141/2_suppl ) that includes a narrative summaries and supporting summary of fi ndings tables. The numbering indicated beside the recommendations in this summary is aligned with the sections and tables found in the full articles. Those interested in a deeper understanding of the evidence can turn to online data supplements for each of the articles that include recommendations. There, they will fi nd evidence profi les (expanded versions of the summary of fi ndings
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VKA Drug Interactions to Avoid
For patients taking VKAs
, we suggest avoiding concomitant treatment with nonsteroidal antiinfl ammatory drugs, including cyclooxygenase-2-selective nonsteroidal antiinfl ammatory drugs, and certain antibiotics (see Table 8 in main article 1 ) (Grade 2C) .
For patients taking VKAs, we suggest avoiding concomitant treatment with antiplatelet agents except in situations where benefi t is known or is highly likely to be greater than harm from bleeding, such as patients with mechanical valves, patients with acute coronary syndrome, or patients with recent coronary stents or bypass surgery (Grade 2C) . 
Optimal Therapeutic INR Range
For patients treated with
Therapeutic Range for High-Risk Groups
For patients with antiphospholipid syn drome with previous arterial or venous thromboembolism,
we suggest VKA therapy titrated to a moderateintensity INR range (INR 2.0-3.0) rather than higher intensity (INR 3.0-4.5) (Grade 2B) .
Discontinuation of Therapy
5
.0. For patients eligible to discontinue treatment with VKA, we suggest abrupt discontinuation rather than gradual tapering of the dose to discontinuation (Grade 2C) .
Unfractionated Heparin (UFH) Dose Adjustment by Weight
6.1. For patients starting IV UFH, we suggest that the initial bolus and the initial rate of the continuous infusion be weight adjusted (bolus 80 units/kg followed by 18 units/kg per h for VTE; bolus 70 units/kg followed by 15 units/kg per h for cardiac or stroke patients) or use of a fi xed dose (bolus 5,000 units followed by 1,000 units/h) rather than alternative regimens (Grade 2C) .
Dose Management of Subcutaneous (SC) UFH
For outpatients with VTE treated with SC
UFH, we suggest weight-adjusted dosing (fi rst dose 333 units/kg, then 250 units/kg) without monitoring rather than fi xed or weightadjusted dosing with monitoring (Grade 2C) .
Monitoring Frequency for VKAs
For patients taking VKA therapy with consistently stable INRs, we suggest an INR testing frequency of up to 12 weeks rather than every 4 weeks (Grade 2B
) .
Management of the Single Out-of-Range INR
For patients taking VKAs with previously stable therapeutic
INRs who present with a single out-of-range INR of Յ 0.5 below or above therapeutic, we suggest continuing the current dose and testing the INR within 1 to 2 weeks (Grade 2C) .
Bridging for Low INRs
For patients with stable therapeutic INRs
presenting with a single subtherapeutic INR value, we suggest against routinely administering bridging with heparin (Grade 2C) .
Vitamin K Supplementation
For patients taking VKAs, we suggest against routine use of vitamin K supplementation (Grade 2C
Anticoagulation Management Services for VKAs
(Best Practices Statement)
We suggest that health-care providers who manage oral anticoagulation therapy should do so in a systematic and coordinated fashion, incorporating patient education, systematic INR testing, tracking, follow-up, and good patient communication of results and dosing decisions.
Patient Self-Testing and Self-Management
For patients treated with
VKAs who are motivated and can demonstrate competency in self-management strategies, including the self-testing equipment, we suggest patient selfmanagement rather than usual outpatient INR monitoring (Grade 2B) . For all other patients, we suggest monitoring that includes the safeguards in our best practice statement 3.5.
Dosing Decision Support
For dosing decisions during maintenance
VKA therapy, we suggest using validated decision support tools (paper nomograms or computerized dosing programs) rather than no decision support (Grade 2C) .
Remarks: Inexperienced prescribers may be more likely to improve prescribing with use of decision support tools than experienced prescribers.
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Executive Summary unfractionated heparin (LDUH) bid, LDUH tid, or fondaparinux (Grade 1B) .
Remarks:
In choosing the specifi c anticoagulant drug to be used for pharmacoprophylaxis, choices should be based on patient preference, compliance, and ease of administration (eg, daily vs bid vs tid dosing), as well as on local factors affecting acquisition costs (eg, prices of various pharmacologic agents in individual hospital formularies).
For acutely ill hospitalized medical patients
at low risk of thrombosis, we recommend against the use of pharmacologic prophylaxis or mechanical prophylaxis (Grade 1B) .
2.7.1. For acutely ill hospitalized medical patients who are bleeding or at high risk for bleeding, we recommend against anticoagulant thromboprophylaxis (Grade 1B) .
For acutely ill hospitalized medical patients at
increased risk of thrombosis who are bleeding or at high risk for major bleeding, we suggest the optimal use of mechanical thromboprophylaxis with graduated compression stockings (GCS) (Grade 2C) or intermittent pneumatic compression (IPC) (Grade 2C) , rather than no mechanical thromboprophylaxis. When bleeding risk decreases, and if VTE risk persists, we suggest that pharmacologic thromboprophylaxis be substituted for mechanical thromboprophylaxis (Grade 2B) .
Remarks:
Patients who are particularly averse to the potential for skin complications, cost, and need for clinical monitoring of GCS and IPC use are likely to decline mechanical prophylaxis.
In acutely ill hospitalized medical patients
who receive an initial course of thromboprophylaxis, we suggest against extending the duration of thromboprophylaxis beyond the period of patient immobilization or acute hospital stay (Grade 2B) .
Critically Ill Patients
3.2.
In critically ill patients, we suggest against routine ultrasound screening for DVT (Grade 2C) .
3.4.3.
For critically ill patients, we suggest using LMWH or LDUH thromboprophylaxis over no prophylaxis (Grade 2C) .
3.4.4.
For critically ill patients who are bleeding, or are at high risk for major bleeding, we suggest mechanical thromboprophylaxis with GCS (Grade 2C) or IPC (Grade 2C) until the
Therapeutic Dose of LMWH in Patients With
Decreased Renal Function 7.1. For patients receiving therapeutic LMWH who have severe renal insuffi ciency (calculated creatinine clearance , 30 mL/min), we suggest a reduction of the dose rather than using standard doses (Grade 2C) .
Fondaparinux Dose Management by Weight
8.1.
For patients with VTE and body weight over 100 kg, we suggest that the treatment dose of fondaparinux be increased from the usual 7.5 mg to 10 mg daily SC (Grade 2C) . 
Vitamin K for Patients Taking VKAs With High INRs Without Bleeding
Clinical Prediction Rules for Bleeding While
Taking VKA 9.2. For patients initiating VKA therapy, we suggest against the routine use of clinical prediction rules for bleeding as the sole criterion to withhold VKA therapy (Grade 2C) .
Treatment of Anticoagulant-Related Bleeding
9.
3. For patients with VKA-associated major bleeding, we suggest rapid reversal of anticoagulation with four-factor prothrombin complex concentrate rather than with plasma. (Grade 2C) .
We suggest the additional use of vitamin K 5 to 10 mg administered by slow IV injection rather than reversal with coagulation factors alone (Grade 2C) .
Prevention of VTE in Nonsurgical Patients
For further details, see Kahn et al. 2 
Hospitalized Acutely Ill Medical Patients
For acutely ill hospitalized medical patients at increased risk of thrombosis, we recom mend anticoagulant thromboprophylaxis with lowmolecular-weight heparin [LMWH], low-dose
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knee GCS providing 15 to 30 mm Hg of pressure at the ankle during travel (Grade 2C) . For all other long-distance travelers, we suggest against the use of GCS (Grade 2C) .
For long-distance travelers, we suggest against the use of aspirin or anticoagulants to prevent VTE (Grade 2C
Persons With Asymptomatic Thrombophilia
7.1. In persons with asymptomatic thrombophilia (ie, without a previous history of VTE), we recommend against the long-term daily use of mechanical or pharmacologic thromboprophylaxis to prevent VTE (Grade 1C) .
Prevention of VTE in Nonorthopedic Surgical Patients
For further details, see Gould et al. 3 
Patients
4.4.
In outpatients with cancer and indwelling central venous catheters, we suggest against routine prophylaxis with LMWH or LDUH (Grade 2B) and suggest against the prophylactic use of VKAs (Grade 2C) .
Chronically Immobilized Patients
In chronically immobilized persons residing
at home or at a nursing home, we suggest against the routine use of thromboprophylaxis (Grade 2C) . Remarks: Three of the seven authors favored a strong (Grade 1B) recommendation in favor of LMWH or LDUH over no prophylaxis in this group.
Persons Traveling Long-Distance
5.4.2.
For thoracic surgery patients at high risk for VTE who are not at high risk for perioperative bleeding, we suggest LDUH (Grade 1B) or LMWH (Grade 1B) over no prophylaxis. In addition, we suggest that mechanical prophylaxis with elastic stockings or IPC should be added to pharmacologic prophylaxis (Grade 2C) .
5.4.3.
For thoracic surgery patients who are at high risk for major bleeding, we suggest use of mechanical prophylaxis, preferably with optimally applied IPC, over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated (Grade 2C) . 
Patients Undergoing Craniotomy
Patients With Isolated Lower-Leg Injuries Distal to the Knee
3.0.
We suggest no prophylaxis rather than pharmacologic thromboprophylaxis in patients with isolated lower-leg injuries requiring leg immobilization (Grade 2C) .
Patients Undergoing Knee Arthroscopy
4.0. For patients undergoing knee arthroscopy without a history of prior VTE, we suggest no thromboprophylaxis rather than prophylaxis (Grade 2B) .
Perioperative Management of Antithrombotic Therapy
For further details, see Douketis et al. 5 2. 
2.5.
In patients undergoing major orthopedic surgery, we suggest using dual prophylaxis with an antithrombotic agent and an IPCD during the hospital stay (Grade 2C) .
Remarks:
We recommend the use of only portable, battery-powered IPCDs capable of recording and reporting proper wear time on a daily basis for inpatients and outpatients. Efforts should be made to achieve 18 h of daily compliance. Patients who place a high value on avoiding the undesirable consequences associated with prophylaxis with both a pharmacologic agent and an IPCD are likely to decline use of dual prophylaxis.
2.6.
In patients undergoing major orthopedic surgery and increased risk of bleeding, we suggest using an IPCD or no prophylaxis rather than pharmacologic treatment (Grade 2C) .
Remarks:
We recommend the use of only portable, battery-powered IPCDs capable of recording and reporting proper wear time on a daily basis for inpatients and outpatients. Efforts should be made to achieve 18 h of daily compliance. Patients who place a high value on avoiding the discomfort and inconve-
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time of the procedure instead of stopping ASA 7 to 10 days before the procedure (Grade 2C 
Surgical Patients With Coronary Stents
3.7.
In patients with a coronary stent who are receiving dual antiplatelet therapy and require surgery, we recommend deferring surgery for at least 6 weeks after placement of a bare-metal stent and for at least 6 months after placement of a drug-eluting stent instead of undertaking surgery within these time periods (Grade 1C) . In patients who require surgery within 6 weeks of placement of a bare-metal stent or within 6 months of placement of a drug-eluting stent, we suggest continuing dual antiplatelet therapy around the time of surgery instead of stopping dual antiplatelet therapy 7 to 10 days before surgery (Grade 2C) .
Remarks:
Patients who are more concerned about avoiding the unknown, but potentially large increase in bleeding risk associated with the perioperative continuation of dual antiplatelet therapy than avoiding the risk for coronary stent thrombosis are unlikely to choose continuation of dual antiplatelet therapy.
Perioperative Use of IV UFH
4.2.
In patients who are receiving bridging anticoagulation with therapeutic-dose IV UFH, we suggest stopping UFH 4 to 6 h before surgery instead of closer to surgery (Grade 2C) .
resuming VKAs approximately 12 to 24 h after surgery (evening of or next morning) and when there is adequate hemostasis instead of later resumption of VKAs (Grade 2C) .
Bridging Anticoagulation During Interruption of VKA Therapy
2.4.
In patients with a mechanical heart valve, atrial fi brillation, or VTE at high risk for thromboembolism, we suggest bridging anticoagulation instead of no bridging during interruption of VKA therapy (Grade 2C) .
Remarks:
Patients who place a higher value on avoiding perioperative bleeding than on avoiding perioperative thromboembolism are likely to decline heparin bridging.
In patients with a mechanical heart valve, atrial fi brillation, or VTE at low risk for thromboembolism, we suggest no bridging instead of bridging anticoagulation during interruption of VKA therapy (Grade 2C) .
In patients with a mechanical heart valve, atrial fi brillation, or VTE at moderate risk for thromboembolism, the bridging or no-bridging approach chosen is, as in the higher-and lower-risk patients, based on an assessment of individual patient-and surgery-related factors. In patients with (i) negative serial proximal CUS or (ii) a negative single proximal CUS and negative moderate or highly sensitive D-dimer, we recommend no further testing rather than further testing with (i) whole-leg US or (ii) venography (Grade 1B for all comparisons) .
Perioperative
If whole-leg US is negative, we recommend no further testing over (i) repeat US in one week, (ii) D-dimer testing, or (iii) venography
(Grade 1B for all comparisons) . If proximal CUS is positive, we recommend treating for DVT rather than confi rmatory venography (Grade 1B) . If isolated distal DVT is detected on wholeleg US, we suggest serial testing to rule out proximal extension over treatment (Grade 2C) .
Remarks:
Patients with abnormal isolated distal US fi ndings on whole-leg US who place a high value on avoiding the inconvenience of repeat testing and a low value on avoiding treatment of false-positive results are likely to choose treatment over repeat US.
Patients with severe symptoms and risk factors for extension as outlined in Perioperative Management of Antithrombotic Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines are more likely to benefi t from treatment over repeat US.
Venography in Patients With Suspected Recurrent DVT
In patients suspected of having recurrent lower extremity DVT, we recommend initial evaluation with proximal CUS or a highly sensitive D-dimer over venography, CT venography, or MRI (all Grade 1B) .
Remarks: Initial D-dimer testing with a high-sensitivity assay is preferable if prior US is not available for comparison.
If the highly sensitive D-dimer is positive, we recommend proximal CUS over venography, CT venography, or MRI (Grade 1B for all com parisons) .
In patients with suspected recurrent lower extremity DVT in whom initial proximal CUS is negative (normal or residual diameter increase of , 2 mm), we suggest at least one further proximal CUS (day 7 Ϯ 1) or testing with a moderately or highly sensitive D-dimer (followed by repeat CUS [day 7 Ϯ 1] if positive) rather than no further testing or venography (Grade 2B) .
Remarks:
In patients with an abnormal proximal CUS at presentation that does not meet the criteria for the diagnosis of recurrence, an additional proximal CUS on day 2 Ϯ 1 in addition to that on (day 7 Ϯ 1) may be preferred. Patients who place a high value on an accurate diagnosis and a low value on avoiding the inconvenience and potential side effects of a venography are likely to choose venography over missed diagnosis (in the case of residual diameter increase of , 2 mm).
We recommend that patients with suspected recurrent lower extremity DVT and a negative highly sensitive D-dimer or negative proximal CUS and negative moderately or highly sensitive D-dimer or negative serial proximal CUS undergo no further testing for suspected recurrent DVT rather than venography (Grade 1B) .
If CUS of the proximal veins is positive, we recommend treating for DVT and performing no further testing over performing confi rmatory venography (Grade 1B for the fi nding of a new noncompressible segment in the common femoral or popliteal vein, Grade 2B for a Ն 4-mm increase in venous diameter during compression compared with that in the same venous segment on a previous result) .
Remarks: Patients with US abnormalities at presentation that do not include a new noncompressible segment who place a high value on an accurate diagnosis and a low value on avoiding the inconvenience Remarks: Whole-leg US may be preferred to proximal CUS in patients unable to return for serial testing and those with severe symptoms consistent with calf DVT or risk factors for extension of distal DVT. In patients with suspected fi rst lower extremity DVT in whom US is impractical (eg, when leg casting or excessive SC tissue or fl uid prevent adequate assessment of compressibility) or nondiagnostic, we suggest that CT scan venography, MR venography, or MR direct thrombus imaging could be used as an alternative to venog raphy.
We recommend that patients with a negative proximal CUS undergo testing with a moderate-or high-sensitivity D-dimer, whole-leg US, or repeat proximal CUS in 1 week over no further testing (Grade 1B) or venography (Grade 2B) . In patients with a negative proximal CUS, we suggest D-dimer rather than routine serial CUS (Grade 2B) or whole-leg US (Grade 2C) . We recommend that patients with a single negative proximal CUS and positive D-dimer undergo further testing with repeat proximal CUS in 1 week or whole-leg US rather than no further testing (Grade 1B for both comparisons) .
We recommend that in patients with (i) negative serial proximal CUS, (ii) a negative D-dimer following a negative initial proximal CUS, or (iii) negative whole-leg US, no further testing be performed rather than venography (Grade 1B) .
If proximal US is positive for DVT, we recommend treatment rather than confi rmatory venography (Grade 1B) . If isolated distal DVT is detected on whole-leg US, we suggest serial testing to rule out proximal extension over treatment (Grade 2C) .
Remarks:
Patients with severe symptoms and risk factors for extension as outlined in "Perioperative Management of Antithrombotic Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines" are more likely to benefi t from treatment over repeat US.
In patients with suspected first lower extremity DVT, we recommend against the routine use of CT venography or MRI (Grade 1C) .
D-dimer done at the time of presentation (Grade 2B) over no further testing for DVT. We recommend that patients with an initial negative proximal CUS and a subsequent negative sensitive D-dimer or negative serial proximal CUS undergo no further testing for DVT (Grade 1B) and that patients with positive D-dimer have an additional follow-up proximal CUS (day 3 and day 7) rather than venography (Grade 1B) or whole-leg US (Grade 2C) . 
Pretest Probability in Pregnancy-
Ultrasonography in Patients With UpperExtremity DVT (UEDVT)
In patients suspected of having UEDVT, we suggest initial evaluation with combined modality US (compression with either Doppler or color Doppler) over other initial tests, including highly sensitive D-dimer or venography (Grade 2C) .
Clinical Pretest Probability Assessment in Patients
With UEDVT 6.2. In patients with suspected UEDVT in whom initial US is negative for thrombosis despite a high clinical suspicion of DVT, we suggest further testing with a moderate or highly sensitive D-dimer, serial US, or venographic-based imaging (traditional, CT scan, or MRI), rather than no further testing (Grade 2C) .
In patients with suspected UEDVT and an initial negative combined-modality US and subsequent negative moderate or highly sensitive D-dimer or CT or MRI, we recommend no further testing, rather than confi rmatory venography (Grade 1C) . We suggest that patients with an initial combined negative modality US and positive D-dimer or those with less than complete evaluation by US undergo venography rather than no further testing, unless there is an alternative explanation for their symptoms (Grade 2B), in which case testing to evaluate for the presence an alternative diagnosis should be performed. We suggest that patients with a positive D-dimer or those with less than complete and potential side effects of a venography are likely to choose venography over treatment (in the case of Ն 4-mm increase in venous diameter). 
Compression Ultrasonography in Patients With
Pretest Probability Assessment in Patients With
Remarks:
Patients who place a high value on avoiding the inconvenience and potential side effects of a venography are likely to choose treatment over venography.
Venography in Pregnancy-Related DVT
5.1.
In pregnant patients suspected of having lower extremity DVT, we recommend initial evaluation with proximal CUS over other initial tests, including a whole-leg US (Grade 2C) , moderately sensitive D-dimer (Grade 2C) , highly sensitive D-dimer (Grade 1B) , or venography (Grade 1B) .
Compression Ultrasonography in PregnancyRelated DVT
5.2.
In pregnant patients with suspected DVT in whom initial proximal CUS is negative, we suggest further testing with either serial proximal CUS (day 3 and day 7) (Grade 1B) or a sensitive
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Executive Summary
Remarks: Patients at high risk for bleeding are more likely to benefi t from serial imaging. Patients who place a high value on avoiding the inconvenience of repeat imaging and a low value on the inconvenience of treatment and on the potential for bleeding are likely to choose initial anticoagulation over serial imaging.
2.3.3.
In patients with acute isolated distal DVT of the leg who are managed with initial anticoagulation, we recommend using the same approach as for patients with acute proximal DVT (Grade 1B) .
2.3.4.
In patients with acute isolated distal DVT of the leg who are managed with serial imaging, we recommend no anticoagulation if the thrombus does not extend (Grade 1B) ; we suggest anticoagulation if the thrombus extends but remains confi ned to the distal veins (Grade 2C) ; we recommend anticoagulation if the thrombus extends into the proximal veins (Grade 1B) .
Timing of Initiation of VKA and Associated Duration of Parenteral Anticoagulant Therapy
2.4.
In patients with acute DVT of the leg, we recommend early initiation of VKA (eg, same day as parenteral therapy is started) over delayed initiation, and continuation of parenteral anticoagulation for a minimum of 5 days and until the international normalized ratio (INR) is 2.0 or above for at least 24 h (Grade 1B) .
Choice of Initial Anticoagulant Regimen in
Patients With Proximal DVT 2.5.1. In patients with acute DVT of the leg, we suggest LMWH or fondaparinux over IV UFH (Grade 2C) and over SC UFH (Grade 2B for LMWH; Grade 2C for fondaparinux) .
Remarks: Local considerations such as cost, availability, and familiarity of use dictate the choice between fondaparinux and LMWH. LMWH and fondaparinux are retained in patients with renal impairment, whereas this is not a concern with UFH .
In patients with acute DVT of the leg treated with LMWH, we suggest once-over twice-daily administration (Grade 2C) .
Remarks: This recommendation only applies when the approved once-daily regimen uses the same daily dose as the twice-daily regimen (ie, the oncedaily injection contains double the dose of each twice-daily injection). It also places value on avoiding an extra injection per day.
evaluation by US but an alternative explanation for their symptoms undergo confi rmatory testing and treatment of this alternative explanation rather than venography (Grade 2C) .
Remarks: Further radiologic testing (serial US or venographic-based imaging or CT/MR to seek an alternative diagnosis) rather than d-dimer testing is preferable in patients with comorbid conditions typically associated with elevated D-dimer levels.
Antithrombotic Therapy for VTE Disease
For further details, see Kearon et al. 7 Remarks: We do not consider that a permanent IVC fi lter, of itself, is an indication for extended anticoagulation.
Initial Anticoagulation for Patients
Early Ambulation of Patients With Acute DVT
2.14. In patients with acute DVT of the leg, we suggest early ambulation over initial bed rest (Grade 2C) .
Remarks: If edema and pain are severe, ambulation may need to be deferred. As per section 4.1, we suggest the use of compression therapy in these patients. 
Long-term Anticoagulation in Patients With
At-Home vs In-Hospital Initial Treatment of Patients
With DVT 2.7. In patients with acute DVT of the leg and whose home circumstances are adequate, we recommend initial treatment at home over treatment in hospital (Grade 1B) .
Remarks:
The recommendation is conditional on the adequacy of home circumstances: well-maintained living conditions, strong support from family or friends, phone access, and ability to quickly return to the hospital if there is deterioration. It is also conditional on the patient feeling well enough to be treated at home (eg, does not have severe leg symptoms or comorbidity).
Catheter-Directed Thrombolysis for Patients With
Acute DVT 2.9. In patients with acute proximal DVT of the leg, we suggest anticoagulant therapy alone over catheter-directed thrombolysis (CDT) (Grade 2C) .
Remarks:
Patients who are most likely to benefi t from CDT (see text), who attach a high value to prevention of postthrombotic syndrome (PTS), and a lower value to the initial complexity, cost, and risk of bleeding with CDT, are likely to choose CDT over anticoagulation alone.
Systemic Thrombolytic Therapy for Patients With
Acute DVT 2.10. In patients with acute proximal DVT of the leg, we suggest anticoagulant therapy alone over systemic thrombolysis (Grade 2C) .
Remarks:
Patients who are most likely to benefi t from systemic thrombolytic therapy (see text), who do not have access to CDT, and who attach a high value to prevention of PTS, and a lower value to the initial complexity, cost, and risk of bleeding with systemic thrombolytic therapy, are likely to choose systemic thrombolytic therapy over anticoagulation alone.
Operative Venous Thrombectomy for Acute DVT
2.11. In patients with acute proximal DVT of the leg, we suggest anticoagulant therapy alone over operative venous thrombectomy (Grade 2C) . Remarks (3.3.1-3.3.2): Choice of treatment in patients with and without cancer is sensitive to the individual patient's tolerance for daily injections, need for laboratory monitoring, and treatment costs. LMWH, rivaroxaban, and dabigatran are retained in patients with renal impairment, whereas this is not a concern with VKA. Treatment of VTE with dabigatran or rivaroxaban, in addition to being less burdensome to patients, may prove to be associated with better clinical outcomes than VKA and LMWH therapy. When these guidelines were being prepared (October 2011), postmarketing studies of safety were not available. Given the paucity of currently available data and that new data are rapidly emerging, we give a weak recommendation in favor of VKA and LMWH therapy over dabigatran and rivaroxaban, and we have not made any recommendations in favor of one of the new agents over the other. Remarks: Local considerations such as cost, availability, and familiarity of use dictate the choice between fondaparinux and LMWH. LMWH and fondaparinux are retained in patients with renal impairment, whereas this is not a concern with UFH. In patients with PE where there is concern about the adequacy of SC absorption or in patients in whom thrombolytic therapy is being considered or planned, initial treatment with IV UFH is preferred to use of SC therapies.
Anticoagulation in Patients Who
Choice of Anticoagulant Regimen for Extended Therapy
In patients with acute PE treated with LMWH, we suggest once-over twice-daily administration (Grade 2C) .
Early vs Standard Discharge of Patients With
Acute PE 5.5. In patients with low-risk PE and whose home circumstances are adequate, we suggest early discharge over standard discharge (eg, after fi rst 5 days of treatment) (Grade 2B) .
same anticoagulant chosen for the fi rst 3 months (Grade 2C) .
Treatment of Patients With Asymptomatic DVT of the Leg
3.5.
In patients who are incidentally found to have asymptomatic DVT of the leg, we suggest the same initial and long-term anticoagulation as for comparable patients with symptomatic DVT (Grade 2B) .
Compression Stockings and Bandages to Prevent PTS
In patients with acute symptomatic DVT of the leg, we suggest the use of compression stockings (Grade 2B) .
Remarks: Compression stockings should be worn for 2 years, and we suggest beyond that if patients have developed PTS and fi nd the stockings helpful.
Patients who place a low value on preventing PTS or a high value on avoiding the inconvenience and discomfort of stockings are likely to decline stockings.
Physical Treatment of Patients With PTS
In patients with PTS of the leg, we suggest a trial of compression stockings (Grade 2C
4.2.2.
In patients with severe PTS of the leg that is not adequately relieved by compression stockings, we suggest a trial of an intermittent compression device (Grade 2B) .
Pharmacologic Treatment of Patients With PTS
4.3.
In patients with PTS of the leg, we suggest that venoactive medications (eg, rutosides, defi brotide, and hidrosmin) not be used (Grade 2C) .
Remarks:
Patients who value the possibility of response over the risk of side effects may choose to undertake a therapeutic trial.
Initial Anticoagulation for Patients With Acute Pulmonary Embolism (PE)
5.1. In patients with acute PE, we recommend initial treatment with parenteral anticoagulation (LMWH, fondaparinux, IV UFH, or SC UFH) over no such initial treatment (Grade 1B) . Remarks: Patients who prefer the security of the hospital to the convenience and comfort of home are likely to choose hospitalization over home treatment. Remarks (6.6-6.7): Choice of treatment in patients with and without cancer is sensitive to the individual patient's tolerance for daily injections, need for laboratory monitoring, and treatment costs. Treatment of VTE with dabigatran or rivaroxaban, in addition to being less burdensome to patients, may prove to be associated with better clinical outcomes than VKA and LMWH therapy. When these guidelines were being prepared (October 2011), postmarketing studies of safety were not available. Given the paucity of currently available data and that new data are rapidly emerging, we give a weak recommendation in favor of VKA and LMWH therapy over dabigatran and rivaroxaban, and we have not made any recommendation in favor of one of the new agents over the other.
Parenteral Anticoagulation Prior to Receipt of the
Systemic Thrombolytic Therapy for Patients With PE
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Executive Summary 
Prevention of PTS of the Arm
Treatment and Prevention of Heparin-Induced Thrombocytopenia
For further details, see Linkins et al. 8 
Platelet Count Monitoring Combined With the 4Ts Score for Patients Receiving Heparin/LMWH
2.1.1. For patients receiving heparin in whom clinicians consider the risk of heparin-induced thrombocytopenia (HIT) to be . 1%, we suggest that platelet count monitoring be performed every 2 or 3 days from day 4 to day 14 (or until heparin is stopped, whichever occurs fi rst) (Grade 2C) .
For patients receiving heparin in whom
clinicians consider the risk of HIT to be , 1%, we suggest that platelet counts not be monitored (Grade 2C) .
Thrombolytic Therapy for the Initial Treatment of Patients With UEDVT
9.2.1. In patients with acute UEDVT that involves the axillary or more proximal veins, we suggest anticoagulant therapy alone over thrombolysis (Grade 2C) .
Remarks:
Patients who (i) are most likely to benefi t from thrombolysis (see text); (ii) have access to CDT; (iii) attach a high value to prevention of PTS; and (iv) attach a lower value to the initial complexity, cost, and risk of bleeding with thrombolytic therapy are likely to choose thrombolytic therapy over anticoagulation alone.
9.2.2.
In patients with UEDVT who undergo thrombolysis, we recommend the same intensity and duration of anticoagulant therapy as in similar patients who do not undergo thrombolysis (Grade 1B) .
Long-term Anticoagulation for Patients With UEDVT
9.3.1. In most patients with UEDVT that is associated with a central venous catheter, we suggest that the catheter not be removed if it is functional and there is an ongoing need for the catheter (Grade 2C) .
9.3.2.
In patients with UEDVT that involves the axillary or more proximal veins, we suggest a minimum duration of anticoagulation of 3 months over a shorter period (Grade 2B) .
Remarks: This recommendation also applies if the UEDVT was associated with a central venous catheter that was removed shortly after diagnosis.
9.3.3.
In patients who have UEDVT that is associated with a central venous catheter that is removed, we recommend 3 months of anticoagulation over a longer duration of therapy in patients with no cancer (Grade 1B) , and we suggest this in patients with cancer (Grade 2C) .
9.3.4.
In patients who have UEDVT that is associated with a central venous catheter that is not removed, we recommend that anticoagulation is continued as long as the central venous catheter remains over stopping after 3 months of treatment in patients with cancer (Grade 1C) , and we suggest this in patients with no cancer (Grade 2C) . 9.3.5. In patients who have UEDVT that is not associated with a central venous catheter or with cancer, we recommend 3 months of anticoagulation over a longer duration of therapy (Grade 1B) .
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and until the INR is within the target range over shorter periods of overlap and that the INR be rechecked after the anticoagulant effect of the nonheparin anticoagulant has resolved (Grade 1C) . thrombosis) , we recommend the use of lepirudin or argatroban or danaparoid over the further use of heparin or LMWH or initiation/continuation of a VKA (Grade 1C) .
Discontinuation of Heparin or Initiation of VKAs vs Treatment With Nonheparin Anticoagulants
In patients with isolated HIT (HIT without
Choice of Nonheparin Anticoagulants in Patients With Isolated HIT
In patients with isolated HIT (HIT without thrombosis) who have normal renal function, we suggest the use of argatroban or lepirudin or danaparoid over other nonheparin anticoagulants (Grade 2C) .
Remarks: Other factors such as drug availability, cost, and ability to monitor the anticoagulant effect may infl uence the choice of agent. The dosing considerations are the same as for patients with HITT (see section 3.2). For a recommendation on choice of nonheparin anticoagulants in the setting of renal insuffi ciency, see Recommendation 3.2.2.
Patients Who Require Urgent Cardiac Surgery
5.1.1.
In patients with acute HIT (thrombocytopenic, HIT antibody positive) or subacute HIT (platelets recovered but still HIT antibody positive) who require urgent cardiac surgery, we suggest the use of bivalirudin over other nonheparin anticoagulants and over heparin plus antiplatelet agents (Grade 2C) .
In patients with acute HIT who require nonurgent cardiac surgery, we recommend delaying the surgery (if possible) until HIT has resolved and HIT antibodies are negative (see section 6.1) (Grade 2C) .
Remarks: Other factors not covered by our analysis, such as drug availability, cost, and ability to monitor the anticoagulant effect may infl uence the choice of agent. For recommendations for patients with a past history of HIT (. 3 months previous) who require cardiac surgery, see section 6.1.
Patients Who Require Urgent Percutaneous Coronary Interventions
In patients with acute HIT or subacute HIT who require percutaneous coronary interventions, we suggest the use of bivalirudin (Grade 2B)
Discontinuation of Heparin or Initiation of VKAs vs Treatment With Nonheparin Anticoagulants
In patients with HIT complicated by thrombosis (HITT)
, we recommend the use of nonheparin anticoagulants, in particular lepirudin, argatroban, and danaparoid, over the further use of heparin or LMWH or initiation/continuation of a VKA (Grade 1C) .
Choice of Nonheparin Anticoagulants in Patients With HITT
In patients with HITT who have normal renal function, we suggest the use of argatroban or lepirudin or danaparoid over other nonheparin anticoagulants (Grade 2C) .
Remarks: Other factors not covered by our analysis, such as drug availability, cost, and ability to monitor the anticoagulant effect, may infl uence the choice of agent.
In patients with HITT and renal insufficiency, we suggest the use of argatroban over other nonheparin anticoagulants (Grade 2C) .
Platelet Transfusions
In patients with HIT and severe thrombocytopenia, we suggest giving platelet transfusions only if bleeding or during the performance of an invasive procedure with a high risk of bleeding (Grade 2C) .
Starting VKAs Before Platelet Recovery
3.4.1.
In patients with strongly suspected or confi rmed HIT, we recommend against starting VKA until platelets have substantially recovered (ie, usually to at least 150 3 10 9 /L) over starting VKA at a lower platelet count and that the VKA be initially given in low doses (maximum, 5 mg of warfarin or 6 mg phenprocoumon) over using higher doses (Grade 1C) .
We further suggest that if a VKA has already been started when a patient is diagnosed with HIT, vitamin K should be administered (Grade 2C) .
Remarks: We place a high value on the prevention of venous limb gangrene and a low value on the cost of the additional days of the parental nonheparin anticoagulant.
Discontinuation of Thrombin Inhibitor After a Minimum of 5 Days of Overlap With VKAs
3.5.
In patients with confi rmed HIT, we recommend that that the VKA be overlapped with a nonheparin anticoagulant for a minimum of 5 days absent who require cardiac catheterization or percutaneous coronary interventions, the recommended treatment is the same as 5.2. HIT) and normal renal function, we suggest the use of fondaparinux at full therapeutic doses until transition to a VKA can be achieved (Grade 2C) .
Patients Who Require Prophylaxis or Treatment of Thrombosis
In patients with a past history of HIT who have acute thrombosis (not related to
Antithrombotic Therapy for Atrial Fibrillation
For further details, see You et al. 9 Remarks: Other factors, such as drug availability, cost, and ability to monitor the anticoagulant effect, may infl uence the choice of agent.
Patients With Nonrheumatic Atrial Fibrillation (AF)
Patients Who Require Renal Replacement Therapy
5.3.1.
In patients with acute or subacute HIT who require renal replacement therapy, we suggest the use of argatroban or danaparoid over other nonheparin anticoagulants (Grade 2C) .
Remarks:
We acknowledge that the cost of argatroban may be prohibitive at some clinical centers. We further suggest that if the prothrombotic state of HIT appears to have resolved (as seen by normalization of the platelet count), saline fl ushes during dialysis would be a reasonable option. This suggestion is based on the presumed pathogenesis of thrombosis in this condition and not on the results of clinical trials.
5.3.2.
In patients with a past history of HIT who require ongoing renal replacement therapy or catheter locking, we suggest the use of regional citrate over the use of heparin or LMWH (Grade 2C) .
Pregnant Patients
In pregnant patients with acute or subacute HIT, we suggest danaparoid over other nonheparin anticoagulants (Grade 2C) . We suggest the use of lepirudin or fondaparinux only if danaparoid is not available (Grade 2C) .
Remarks: Other factors, such as drug availability, cost, and ability to monitor the anticoagulant effect, may infl uence the choice of agent. 
Patients With a History of HIT
1).
Remarks : Patients who place an exceptionally high value on stroke reduction and a low value on avoiding bleeding and the burden associated with anticoagulant therapy are likely to choose adjusted-dose VKA therapy plus single antiplatelet therapy rather than dual antiplatelet therapy. Other factors that may infl uence this choice are a consideration of bleeding risk and the presence of additional non-CHADS 2 risk factors for stroke (see section 2.1.12).
Patients With AF Managed by a Rhythm Control Strategy
3.4.
For patients with AF being managed with a rhythm control strategy (pharmacologic or catheter ablation), we suggest that antithrombotic therapy decisions follow the general risk-based recommendations for patients with AF in section 2.1, regardless of the apparent persistence of normal sinus rhythm (Grade 2C) .
Patients With Atrial Flutter
3.5.
For patients with atrial fl utter, we suggest that antithrombotic therapy decisions follow the same risk-based recommendations as for AF. 
Patients Undergoing Elective Cardioversion of AF
Patients With Nonbacterial Thrombotic Endocarditis
In patients with nonbacterial thrombotic endocarditis and systemic or pulmonary emboli, we suggest treatment with full-dose IV UFH or SC LMWH over no anticoagulation (Grade 2C) .
for long-term antithrombotic therapy in section 2.1. Remarks: Caution should be used in patients at increased bleeding risk, such as history of GI bleeding.
Patients Undergoing Elective or Urgent Cardioversion for Atrial Flutter
Antiplatelet Agent Therapy Instead of VKA Therapy
For patients with mechanical aortic or mitral valves we recommend VKA over antiplatelet agents (Grade 1B) .
Antithrombotic Therapy After Mitral Valve Repair
In patients undergoing mitral valve repair
with a prosthetic band in normal sinus rhythm, we suggest the use of antiplatelet therapy for the fi rst 3 months over VKA therapy (Grade 2C) .
Patients Undergoing Aortic Valve Repair
In patients undergoing aortic valve repair,
we suggest aspirin at 50 to 100 mg/d over VKA therapy (Grade 2C) .
Patients With Right-Sided Prosthetic Valve Thrombosis
For patients with right-sided prosthetic valve thrombosis (PVT)
, in the absence of contraindications we suggest administration of fi brinolytic therapy over surgical intervention (Grade 2C) . 
Patients With Left-Sided Prosthetic Valve Thrombosis
Long-term Antithrombotic Therapy for Patients With Bioprosthetic Valves
In patients with bioprosthetic valves in nor-
mal sinus rhythm, we suggest aspirin therapy over no aspirin therapy after 3 months postoperative (Grade 2C) .
Early Postoperative Bridging to Intermediate/ Long-term Therapy (Postoperative Day 0 to 5)
9.1. In patients with mechanical heart valves, we suggest bridging with unfractionated heparin (UFH, prophylactic dose) or LMWH (prophylactic or therapeutic dose) over IV therapeutic UFH until stable on VKA therapy (Grade 2C) .
Long-term Antithrombotic Therapy for Patients With Mechanical Valves
9.2.
In patients with mechanical heart valves, we recommend VKA therapy over no VKA therapy for long-term management (Grade 1B) .
Intensity of VKA Therapy for Patients With Mechanical Aortic Valve Prostheses
9.3.1. In patients with a mechanical aortic valve, we suggest VKA therapy with a target of 2.5 (range, 2.0-3.0) over lower targets (Grade 2C) .
9.3.2.
In patients with a mechanical aortic valve, we recommend VKA therapy with a target of 2.5 (range 2.0-3.0) over higher targets (Grade 1B) .
Intensity of VKA Therapy for Patients With Mechanical Mitral Valve Prostheses
In patients with a mechanical mitral valve, we suggest VKA therapy with a target of
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higher than the associated risks may choose this intervention.
Aspirin in Patients With Acute Ischemic Stroke
In patients with acute ischemic stroke or transient ischemic attack (TIA)
, we recommend early (within 48 h) aspirin therapy at a dose of 160 to 325 mg over no aspirin therapy (Grade 1A).
Anticoagulation in Patients With Acute Ischemic Stroke
2.5.
In patients with acute ischemic stroke or TIA, we recommend early (within 48 h) aspirin therapy with an initial dose of 160 to 325 mg over therapeutic parenteral anticoagulation (Grade 1A).
VTE Prevention in Patients With Ischemic Stroke
3.1.1. In patients with acute ischemic stroke and restricted mobility, we suggest prophylacticdose SC UFH or LMWH or intermittent pneumatic compression devices over no prophylaxis (Grade 2B).
In patients with acute ischemic stroke and restricted mobility, we suggest prophylactic-dose LMWH over prophylactic-dose UFH (Grade 2B).
In patients with acute stroke and restricted mobility, we suggest against elastic compression stockings (Grade 2B).
Remarks: Pharmacologic and mechanical prophylaxis should be initiated as early as possible and should be continued throughout the hospital stay or until the patient has regained mobility. Mechanical devices should be temporarily removed as often as needed to allow for early mobilization and screening for skin complications.
Combining pharmacologic therapy with intermittent pneumatic compression devices may yield additional benefi t in prevention of VTEs compared with either method used alone.
VTE Prevention in Patients With Hemorrhagic Stroke
3.2.1.
In patients with acute primary intracerebral hemorrhage and restricted mobility, we suggest prophylactic-dose SC heparin (UFH or LMWH) started between days 2 and 4 or intermittent pneumatic compression devices over no prophylaxis (Grade 2C).
In patients with acute primary intracerebral hemorrhage and restricted mobility, we suggest prophylactic-dose LMWH over prophylactic-dose UFH (Grade 2B).
administration of fi brinolytic therapy over surgery. For very small, nonobstructive thrombus we suggest IV UFH accompanied by serial Doppler echocardiography to document thrombus resolution or improvement over other alternatives (Grade 2C) .
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
For further details, see Lansberg et al. 11 
IV Recombinant Tissue Plasminogen Activator (r-tPA) for Patients With Acute Ischemic Stroke
2.1.1. In patients with acute ischemic stroke in whom treatment can be initiated within 3 h of symptom onset, we recommend IV r-tPA over no IV r-tPA (Grade 1A).
2.1.2.
In patients with acute ischemic stroke in whom treatment can be initiated within 4.5 but not within 3 h of symptom onset, we suggest IV r-tPA over no IV r-tPA (Grade 2C).
2.1.3.
In patients with acute ischemic stroke in whom treatment cannot be initiated within 4.5 h of symptom onset, we recommend against IV r-tPA (Grade 1B).
Intraarterial Thrombolysis in Patients With
Acute Ischemic Stroke 2.2.1. In patients with acute ischemic stroke due to proximal cerebral artery occlusions who do not meet eligibility criteria for treatment with IV r-tPA, we suggest intraarterial (IA) r-tPA initiated within 6 h of symptom onset over no IA r-tPA (Grade 2C).
2.2.2.
In patients with acute ischemic stroke we suggest IV r-tPA over the combination IV/IA r-tPA (Grade 2C).
Remarks: Carefully selected patients who value the uncertain benefi ts of combination IV/IA thrombolysis higher than the associated risks may choose this intervention. Patients who prefer to avoid risk in the setting of uncertain benefi ts are more likely to choose IV r-tPA alone.
Mechanical Thrombectomy in Patients With
Acute Ischemic Stroke 2.3. In patients with acute ischemic stroke, we suggest against the use of mechanical thrombectomy (Grade 2C).
Remarks: Carefully selected patients who value the uncertain benefi t of mechanical thrombectomy recommend combination therapy with aspirin and clopidogrel over aspirin (Grade 1B).
Remarks: Patients should be treated (ie, bridged) with aspirin until anticoagulation has reached a therapeutic level.
Oral anticoagulation should generally be initiated within 1 to 2 weeks after stroke onset. Earlier anticoagulation can be considered for patients at low risk of bleeding complications (eg, those with a small infarct burden and no evidence of hemorrhage on brain imaging). Delaying anticoagulation should be considered for patients at high risk of hemorrhagic complications (eg, those with extensive infarct burden or evidence of signifi cant hemorrhagic transformation on brain imaging).
Dabigatran is excreted primarily by the kidney. It has not been studied and is contraindicated in patients with severe renal impairment (estimated creatinine clearance of 30 mL/min or less).
Antithrombotic Therapy for Stroke Prevention in Patients With a History of Intracerebral Hemorrhage (ICH)
In patients with a history of a symptomatic primary ICH, we suggest against the long-term use of antithrombotic therapy for the prevention of ischemic stroke (Grade 2C).
Remarks: Patients who might benefi t from antithrombotic therapy are those at relatively low risk of recurrent ICH (eg, with deep hemorrhages) and relatively high risk (. 7% per year) of throm boembolic events (eg, with mechanical heart valves or CHADS 2 (Congestive heart failure, Hypertension, Age . 75, Diabetes mellitus, Stroke or TIA) score . 4 points).
Anticoagulation for Patients With Symptomatic Cerebral Venous Sinus Thrombosis
In patients with cerebral venous sinus thrombosis, we suggest anticoagulation over no anticoagulant therapy during the acute and chronic phases (Grade 2C).
Remarks: Patients with a history of ICH who might benefi t from antithrombotic therapy are those at relatively low risk of recurrent ICH (eg, with deep hemorrhages) and relatively high risk (. 7% per year) of cardiac thromboembolic events (eg, with mechanical heart valves or CHADS 2 score . 4 points).
The Primary and Secondary Prevention of Cardiovascular Disease
For further details, see Vandvik et al. 12 3.2.3. In patients with primary intracerebral hemorrhage and restricted mobility, we suggest against elastic compression stockings (Grade 2B).
Remarks:
Patients who prefer to avoid a theoretically increased risk of rebleeding with heparin would favor mechanical prophylaxis with intermittent pneumatic compression devices over pharmacologic prophylaxis.
Antithrombotic Therapy for the Secondary Prevention of Noncardioembolic Stroke
4.1.1. In patients with a history of noncardioembolic ischemic stroke or TIA, we recommend long-term treatment with aspirin (75-100 mg once daily), clopidogrel (75 mg once daily), aspirin/ extended-release dipyridamole (25 mg/200 mg bid), or cilostazol (100 mg bid) over no antiplatelet therapy (Grade 1A), oral anticoagulants (Grade 1B), the combination of clopidogrel plus aspirin (Grade 1B), or trifl usal (grade 2B).
Of the recommended antiplatelet regimens, we suggest clopidogrel or aspirin/extendedrelease dipyridamole over aspirin (Grade 2B) or cilostazol (Grade 2C).
Remarks: With long-term use (. 5 y), the benefi t of clopidogrel over aspirin in preventing major vascular events may be offset by a reduction in cancer-related mortality with regimens that contain aspirin.
Antithrombotic Therapy for the Secondary Prevention of Cardioembolic Stroke
4.2.1.
In patients with a history of ischemic stroke or TIA and AF, includ ing paroxysmal AF, we recommend oral anticoagulation over no antithrombotic therapy (Grade 1A), aspirin (Grade 1B), or combination therapy with aspirin and clopidogrel (Grade 1B).
4.2.2.
In patients with a history of ischemic stroke or TIA and atrial fi brillation, including paroxysmal AF, we suggest oral anticoagulation with dabigatran 150 mg bid over adjusted-dose VKA therapy (target range, 2.0-3.0) (Grade 2B).
4.2.3.
In patients with a history of ischemic stroke or TIA and atrial fi brillation, including paroxysmal AF, who are unsuitable for or choose not to take an oral anticoagulant (for reasons other than concerns about major bleeding), we daily plus low-dose aspirin, or prasugrel 10 mg daily plus low-dose aspirin over single antiplatelet therapy) (Grade 1B) .
Remarks: Evidence suggests that prasugrel results in no benefi t net harm in patients with a body weight of , 60 kg, age . 75 years, or with a previous stroke/ transient ischemic attack.
• We suggest ticagrelor 90 mg twice daily plus low-dose aspirin over clopidogrel 75 mg daily plus low-dose aspirin (Grade 2B) . 
For patients with ACS
Primary Prevention of Cardiovascular Disease
2.1. For persons aged 50 years or older without symptomatic cardiovascular disease, we suggest low-dose aspirin 75 to 100 mg daily over no aspirin therapy (Grade 2B) .
Remarks: Aspirin slightly reduces total mortality regardless of cardiovascular risk profi le if taken over 10 years. In people at moderate to high risk of cardiovascular events, the reduction in myocardial infarction (MI) is closely balanced with an increase in major bleeds. Whatever their risk status, people who are averse to taking medication over a prolonged time period for very small benefi ts will be disinclined to use aspirin for primary prophylaxis. Individuals who value preventing an MI substantially higher than avoiding a GI bleed will be, if they are in the moderate or high cardiovascular risk group, more likely to choose aspirin. • We recommend long-term single antiplatelet therapy with aspirin 75 to 100 mg daily or clopidogrel 75 mg daily over no antiplatelet therapy (Grade 1A) .
Choice of Long-term Antithrombotic Therapy in
• We suggest single over dual antiplatelet therapy with aspirin plus clopidogrel (Grade 2B) .
Choice of Antithrombotic Therapy Following ACS
3.2.1-3.2.5. For patients in the fi rst year after an ACS who have not undergone percutaneous coronary intervention (PCI):
• We recommend dual antiplatelet therapy (ticagrelor 90 mg twice daily plus low-dose aspirin 75-100 mg daily or clopidogrel 75 mg daily plus low-dose aspirin 75-100 mg daily) over single antiplatelet therapy (Grade 1B) .
• We suggest ticagrelor 90 mg daily plus lowdose aspirin over clopidogrel 75 mg daily plus low-dose aspirin (Grade 2B) .
For patients in the fi rst year after an ACS who have undergone PCI with stent placement:
• We recommend dual antiplatelet therapy (ticagrelor 90 mg twice daily plus low-dose aspirin 75-100 mg daily, clopidogrel 75 mg as per the established CAD recommendations (see recommendations 3. 1.1-3.1.5 ).
For patients who have undergone elective BMS or DES stent placement:
• We recommend using low-dose aspirin 75 to 100 mg daily and clopidogrel 75 mg daily alone rather than cilostazol in addition to these drugs (Grade 1B) .
• We suggest aspirin 75 to 100 mg daily or clopidogrel 75 mg daily as part of dual antiplatelet therapy rather than the use of either drug with cilostazol (Grade 1B) .
• We suggest cilostazol 100 mg twice daily as substitute for either low-dose aspirin 75 to 100 mg daily or clopidogrel 75 mg daily as part of a dual antiplatelet regimen in patients with an allergy or intolerance of either drug class (Grade 2C) .
For patients with CAD undergoing elective PCI but no stent placement:
• We suggest for the fi rst month dual antiplatelet therapy with aspirin 75 to 325 mg daily and clopidogrel 75 mg daily over single antiplatelet therapy (Grade 2C) . Single antiplatelet therapy thereafter is recommended as per the established CAD recommendations (see recommendations 3.1.1-3.1.5).
Antithrombotic Therapy in Patients With Systolic LV Dysfunction
5.1-5.3. For patients with systolic LV dysfunction without established CAD and no LV thrombus, we suggest not to use antiplatelet therapy or warfarin (Grade 2C) .
Remarks: Patients who place a high value on an uncertain reduction in stroke and a low value on avoiding an increased risk of GI bleeding are likely to choose to use warfarin. 
Antithrombotic Therapy in Peripheral Artery Disease
For further details, see Alonso-Coello et al. 13 For patients with anterior MI and LV thrombus, or at high risk for LV thrombus (ejection fraction , 40%, anteroapical wall motion abnormality) who undergo drug-eluting stent (DES) placement:
• For patients who have undergone elective PCI with placement of DES:
• For the fi rst 3 to 6 months, we recommend dual antiplatelet therapy with aspirin 75 to 325 mg daily and clopidogrel 75 mg daily over single antiplatelet therapy (Grade 1A) .
Remarks: Absolute minimum duration will vary based on stent type (in general, 3 months for -limus stents and 6 months for -taxel stents).
• After 3 to 6 months, we suggest continuation of dual antiplatelet therapy with lowdose aspirin 75 to 100 mg and clopidogrel (75 mg daily) until 12 months over single antiplatelet therapy (Grade 2C) .
• After 12 months, we recommend single antiplatelet therapy over continuation of dual antiplatelet therapy (Grade 1B) . Single antiplatelet therapy thereafter is recommended
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than avoidance of a high likelihood of drug-related side effects will be disinclined to take prostanoids. 
Acute Limb Ischemia
Primary Prevention of Cardiovascular Events in Patients with Asymptomatic PAD
2.1. For persons with asymptomatic peripheral arterial disease (PAD), we suggest aspirin 75 to 100 mg daily over no aspirin therapy (Grade 2B) .
Remarks: Aspirin slightly reduces total mortality regardless of cardiovascular risk profi le if taken over 10 years. In people at moderate to high risk of cardiovascular events, the reduction in myocardial infarction (MI) is closely balanced with an increase in major bleeds. Whatever their risk status, people who are averse to taking medication over a prolonged time period for very small benefi ts will be disinclined to use aspirin for primary prophylaxis. Individuals who value preventing an MI substantially higher than avoiding a GI bleed, if they are in the moderate or high cardiovascular risk group, will be more likely to choose aspirin. Remarks : Women who are averse to taking medication for very small benefi t and those who consider self-injecting a considerable burden will be disinclined to use LMWH for extended thrombosis prophylaxis. Given that the absolute benefi t decreases as time from the hyperstimulation event increases, such
Secondary Prevention of Cardiovascular Events in Patients with
Remarks: Aspirin slightly reduces total mortality regardless of cardiovascular risk profi le if taken over 10 years. In people at moderate to high risk of cardiovascular events, the reduction in MI is closely balanced with an increase in major bleeds. Whatever their risk status, people who are averse to taking medication over a prolonged time period for very small benefi ts will be disinclined to use aspirin for primary prophylaxis. Remarks : Women who place little value on avoiding the risks, inconvenience, and costs of LMWH therapy of uncertain duration while awaiting pregnancy and a high value on minimizing the risks of early miscarriage associated with VKA therapy are likely to choose LMWH while attempting pregnancy.
women will be very disinclined to continue prophylaxis throughout the entire resultant pregnancy. 
VTE Following Cesarean Section
LMWH in Neonates and Children
1.2.
We suggest, for neonates and children receiving either once-or twice-daily therapeutic LMWH that the drug be monitored to a target anti-Xa activity range of 0.5 to 1.0 units/mL in a sample taken 4 to 6 h after SC injection or 0.5 to 0.8 units/mL in a sample taken 2 to 6 h after SC injection (Grade 2C) . 
VKAs in Neonates and Children
Values and preferences:
Parents who place a high value on avoiding the inconvenience, discomfort, and limitations of anticoagulant monitoring and a lower value on the uncertain reduction in thrombotic complications are unlikely to choose VKA ther apy for their children who are eligible for transplant.
present in the basket of the fi lter and when contraindication to anticoagulation is resolved (Grade 2C) . In children who receive an IVC fi lter, we recommend appropriate anticoagulation for VTE (see 1.2) as soon as the contraindication to anticoagulation is resolved (Grade 1C) .
DVT in Children With Cancer
2.25. In children with cancer, we suggest that management of VTE follow the general recommendations for management of VTE in children. We suggest the use of LMWH in the treatment of VTE for a minimum of 3 months until the precipitating factor has resolved (eg, use of asparaginase) (Grade 2C) .
Remarks : The presence of cancer, the need for surgery, chemotherapy, or other treatments may modify the risk-benefi t ratio for treatment of VTE, and clinicians should consider these factors on an individual basis. ical Pharmacy, the American Society of Health-System Pharmacists, the American Society of Hematology, and the International Society of Thrombosis and Hematosis.
Children With APLAs and DVT
or VKAs for at least 3 months (Grade 2C 
